Song 2006.

Study characteristics
Methods	Aim: to evaluate changes in depression and cognitive impairment in people with post‐stroke depression treated with fluoxetine Parallel trial
Participants	Country: China Setting: inpatient Stroke diagnosed by clinical criteria and "proved on CT" (though not clear if lesion had to be visible) Depression: diagnosed in accordance with the CCMD‐II‐R Treatment: 41 people, mean age 51 ± 7 years, 25 men), time since stroke: 3.5 days Control: 41 people, mean age 50 ± 8 years, 24 men), time since stroke: 3.7 days Excluded: previous mental disorders, previous "neurological disorder", if other psychiatric drugs had been taken, these had to be stopped for 1 week before fluoxetine was administered
Interventions	Treatment: fluoxetine 20 mg daily Control: placebo (although not stated whether this was identical to fluoxetine) Duration of treatment: 6 weeks Duration of follow‐up (treatment end to study end): 0 Side effects not reported
Outcomes	SDS P300 (an event‐related potential) Although the stated aim was to assess cognitive impairment, it is not clear how this was measured
Funding source	Source of funding not stated
Notes	Recruitment: December 1999 to June 2003. Conflicts of interest not stated
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Placebo, but not clear whether identical
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts
Selective reporting (reporting bias)	Unclear risk	Unclear
Other bias	Unclear risk	Balanced baseline